Allarity Therapeutics, Inc. filed a Form 8-K with the SEC on November 19, 2026, disclosing that the United States Patent and Trademark Office had granted a U.S. patent covering certain stenoparib treatment regimens, as announced in a press release dated November 18, 2026.
Key Highlights
- Patent granted: The United States Patent and Trademark Office granted a U.S. patent covering certain stenoparib treatment regimens, according to the filing.
- Announcement date: The company issued a press release on November 18, 2026, disclosing the patent grant.
- Exchange and ticker: Allarity Therapeutics common stock (par value $0.0001 per share) is listed on NASDAQ:ALLR.
- Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
- Signed by: The filing was signed by Thomas H. Jensen, Chief Executive Officer, on November 19, 2026.
Allarity Therapeutics Discloses USPTO Patent Grant for Stenoparib
Allarity Therapeutics, Inc. (NASDAQ:ALLR) filed a Current Report on Form 8-K on November 19, 2026, reporting an event dated November 18, 2026. Under Item 8.01 (Other Events), the company disclosed that the United States Patent and Trademark Office had granted a U.S. patent covering certain stenoparib treatment regimens. The filing states that a press release announcing the patent grant was issued on November 18, 2026, and is filed as Exhibit 99.1 to the Current Report.
The 8-K does not provide additional technical detail about the scope of the patent or the specific treatment regimens covered beyond what is referenced in the press release exhibit. The filing identifies Thomas H. Jensen as Chief Executive Officer and the authorized signatory on behalf of Allarity Therapeutics, Inc. The company is incorporated in Delaware and lists its principal executive offices at 123 E Tarpon Ave, Tarpon Springs, FL 34689.
Allarity Therapeutics indicated it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The company did not indicate that it has elected to use the extended transition period for complying with new or revised financial accounting standards.
What Was Disclosed
Allarity Therapeutics reported via an 8-K that the USPTO granted a U.S. patent on certain stenoparib treatment regimens. The announcement was made through a press release dated November 18, 2026, attached as Exhibit 99.1 to the filing.



Please wait processing your request...